Abstract: Disclosure of the present invention relates to a method for synthesis of a xylose derivative, which comprises protecting a xylose with a protective group, followed by incorporating to a halogen atom as a leaving group; removing the protective groups and using water-soluble ligands to carry out a Suzuki cross-couplings reaction with a palladium catalyst in a water solution. Ten new xylose derivatives as obtained by the method are also provided.

Abstract: Disclosed is a method of manufacturing graphene material, including steps of first oxidation, first heating, second heating, second oxidation, separation, drying, first ultrasonic vibration, reduction, second ultrasonic vibration, heating, and filtration. The first oxidation and the second oxidation respectively employ the first oxidant and the second oxidant with different strength of oxidation to appropriately control the range of the ratio of carbon vs. oxygen content in the graphene oxide. Therefore, the resultant graphene material through the reduction process has resistivity within 1.45˜150 ?/cm.

Abstract: The present invention relates to a new use of citral for manufacturing a medicament for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that citral is effective in alleviating symptoms of FSGS, including reducing glomerular epithelial hyperplasia lesions (EPHLs), peri-glomerular inflammation or glomerular hyalinosis or sclerosis, and also reducing proteinuria or hematuria or lowering serum urea nitrogen level or serum creatinine level in the subject.

Abstract: The present invention relates to a new use of citral for manufacturing a medicament for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that citral is effective in alleviating symptoms of FSGS, including reducing glomerular epithelial hyperplasia lesions (EPHLs), peri-glomerular inflammation or glomerular hyalinosis or sclerosis, and also reducing proteinuria or hematuria or lowering serum urea nitrogen level or serum creatinine level in the subject.

Abstract: Provided is a quinoline derivative of Chemical Formula (I): wherein, R1 is a substituted or unsubstituted phenyl group, R2 is a halogen, and R3 is a substituted or unsubstituted phenyl group, and one of the carbon atoms in the phenyl ring of the phenyl group is optionally substituted by a nitrogen atom (N). The quinoline derivative can efficiently inhibit cancer cell proliferation and can be used for treating cancer, especially for treating cancers related to the Janus kinase-signal transducers and activators of transcription (JAK-STAT) pathway and/or the mitogen-activated protein kinase (MAPK) pathway.

Abstract: Provided is a quinoline derivative of Chemical Formula (I): wherein, R1 is a substituted or unsubstituted phenyl group, R2 is a halogen, and R3 is a substituted or unsubstituted phenyl group, and one of the carbon atoms in the phenyl ring of the phenyl group is optionally substituted by a nitrogen atom (N). The quinoline derivative can efficiently inhibit cancer cell proliferation and can be used for treating cancer, especially for treating cancers related to the Janus kinase-signal transducers and activators of transcription (JAK-STAT) pathway and/or the mitogen-activated protein kinase (MAPK) pathway.

Abstract: Disclosed are an Schisandrae fructus extract for inhibition or prevention of influenza and its application, wherein the Schisandrae fructus extract is obtained by water, methanol, or ethanol extraction process and the extract comprises compounds such as schisandrone, benzoylgomisin P, wulignan A1, epigomisin O, epiwulignan A1, and tigloylgomisin P. The extracts and purified compounds of Schisandrae fructus has anti-influenza virus H1N1 and H1N1-TR (a Tamiflu drug resistant virus strain) activities, therefore the extracts and the purified compounds of Schisandrae fructus can be applied as an inhitibory agent of a pharmaceutical composition for treatment or prevention agent for influenza infection.

Abstract: Disclosed are an Schisandrae fructus extract for inhibition or prevention of influenza and its application, wherein the Schisandrae fructus extract is obtained by water, methanol, or ethanol extraction process and the extract comprises compounds such as schisandrone, benzoylgomisin P, wulignan A1, epigomisin O, epiwulignan A1, and tigloylgomisin P. The extracts and purified compounds of Schisandrae fructus has anti-influenza virus H1N1 and H1N1-TR (a Tamiflu drug resistant virus strain) activities, therefore the extracts and the purified compounds of Schisandrae fructus can be applied as an inhitibory agent of a pharmaceutical composition for treatment or prevention agent for influenza infection.

Abstract: The invention provides a herbal extract having anti-influenza virus activity, by extracting Sophora flavescens Ait, Thesium chinense Turcz, licorice, or mixture thereof with solvent.

Abstract: This invention discloses a method for diagnosing Crescentic glomerulonephritis (CRGN) using at least a sample from a patient. The method is to find a least one biomarker for diagnosing Crescentic glomerulonephritis. The genetic performance of Sparc, Lcn2 and/or Spp1 can be used as biomarkers.

Abstract: The present invention provides biomarkers for detecting kidney disease, selected from the oligonucleotide sequence, complementary sequence or derivatives, amino acid sequence or derivatives, fragment, variants, antibody of annexin A2 or S100A6 or combinations thereof. Moreover, the present invention also provides an assay kit and a method for kidney disease detecting, practically for the kidney disease resulting from acute tubular necrosis.